An Evaluation of Radionuclide Bone Scanning and Liver Ultrasonography for Staging Breast Cancer

Cox, Michael R.; Giluland, R.; Odling-Smee, G. W.; Spence, Robert

doi:10.1111/j.1445-2197.1992.tb07049.x

Cited by 18 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most common metastatic sites include bone, lung, and liver. Previous studies proposed unnecessary examinations without affecting the efficacy of diagnosis and treatment [3,4], in order to save health expenditure and provide optimal use of resources.…”

Section: Introductionmentioning

confidence: 99%

Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer

Chen

Sun

Cong

et al. 2014

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundBone scanning (BS), liver ultrasonography (LUS), and chest radiography (CXR) are commonly recommended for baseline staging in patients with newly diagnosed breast cancer. The purpose of this study is to demonstrate whether these tests are indicated for specific patient subpopulation based on clinical staging and molecular subtype.MethodsA retrospective study on 5406 patients with newly diagnosed breast cancer was conducted to identify differences in occurrence of metastasis based on clinical staging and molecular subtypes. All patients had been evaluated by BS, LUS and CXR at diagnosis.ResultsComplete information on clinical staging was available in 5184 patients. For stage I, II, and III, bone metastasis rate was 0%, 0.6% and 2.7%, respectively (P < 0.01); liver metastasis rate was 0%, 0.1%, and 1.0%, respectively (P < 0.01); lung metastasis rate was 0.1%, 0.1%, and 0.7%, respectively (P < 0.01). Complete information on molecular subtype was available in 3411 patients. For Luminal A, Luminal B (HER2-), Luminal BH (HER2+), HER2+ overexpression, and Basal-like, bone metastasis rate was 1.4%, 0.7%, 2.5%, 2.7%, and 0.9%, respectively (P < 0.05); liver metastasis rate was 0.1%, 0.1%, 1.0%, 1.1%, and 0.9%, respectively (P < 0.01); lung metastasis rate was 0.20%, 0%, 0%, 0.27%, and 0.9%, respectively (P < 0.05). cT (tumor size), cN (lymph node), PR (progesterone receptor), and HER2 status predicted bone metastasis (P < 0.05). cT, cN, ER (estrogen receptor), PR, and HER2 status predicted liver metastasis (P < 0.05). cT, cN, and PR status predicted lung metastasis (P < 0.05).ConclusionThese data indicate that based on clinical staging and molecular subtypes, BS, LUS and CXR are necessary for patients with newly diagnosed breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer

Chen

Sun

Cong

et al. 2014

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…The interest of the extension assessment is not recommended by the majority of authors for the early stages [20] [21] [22]. However, the authors always recommend the extension assessment in patients with stage III breast cancer [22] [23].…”

Section: Discussionmentioning

confidence: 99%

Mucinous Breast Carcinoma: Anatomo-Clinical Radiological and Therapeutic Features

Korbi¹,

Mhabrech²,

Ennaceur³

et al. 2018

OALib

View full text Add to dashboard Cite

Introduction: Mucinous carcinoma of the breast constitutes 1% to 4% of all breast cancers. Two different forms of presentation are distinguished: pure mucinous carcinoma and mixed mucinous carcinoma. The purpose of our work was to clarify the anatomo-clinical and radiological particularities of this rare form of breast cancer. Materials and methods: This was a retrospective study of a series of 14 cases of mucinous carcinoma of the breast, including 8 pure mucinous carcinomas and 6 mixed mucinous carcinomas treated at the Maternity and Neonatal Center of Monastir between January 2009 and December 2017. Results: The frequency of mucinous carcinoma of the breast in our study period was 1.9%. The average of the patients was 55 years old. The average tumor size was 40 mm. Mucinous carcinoma of the breast was pure in 8 cases, mixed in 6 cases. The clinical size of pure CM was smaller than that of mixed CM (41 mm vs 45 mm) [p = 0.12]. Axillary adenopathies were found in 28.5% of patients. Mammography detected a total of 19 masses with three cases of multifocality. The average size was 27 mm, there was no significant difference between subtype sizes. Pure CMs had an oval shape in 83% of the cases with microlobulated contours in half of the cases, mixed CM rather had an irregular shape (71%) with indistinct contours (85%) (p = 0.01/p = 0.04). On ultrasound, pure CMs had a homogeneous hypoechogenic oval mass appearance with microlobulated contours enhancing ultrasound. The mixed CMs had an irregular shape of non-geometric contours and heterogeneous hypoechogenic appearance with posterior ultrasound attenuation (p = 0.06). Microcalcifications were present in 37% of pure CM and 60% of mixed CM (p = 0.13). Ganglionic invasion was noted in 28% of cases. The extension assessment was negative in all cases.

show abstract

“…15,16 LUS detected liver metastasis very rarely in pathological stage I-II disease and approximately 2-3% in stage III disease. 17,18 Chest x-ray has the lowest detection rate of all staging investigations. Occult metastasis in lungs was detected at a rate of 0.1-2% with chest x-ray.…”

Section: Discussionmentioning

confidence: 99%

“…Although, many anaesthetists traditionally require CXR before general anaesthesia, there is no strong medical indication for routine preoperative CXR in asymptomatic, otherwise healthy breast cancer patients. 17 Furthermore, CXR has never been shown to improve outcome in the care of patients with clinical stage I or II breast cancer. Our data support the view that CXR may be eliminated in the routine staging for asymptomatic patients with stage I or II breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Need for Routine X-Ray Chest and Ultrasonography of Liver in Workup, Diagnosis and Staging of Early Carcinoma of Breast in Patients Presenting First Time: A Prospective Single Institutional Study

Rao¹,

M²

2016

jemds

View full text Add to dashboard Cite

BACKGROUNDCarcinoma breast is a common malignant tumour in urban Indian women and second common among the rural. Early diagnosis and prompt treatment reduces the incidence of metastases and complication. The work-up and staging of invasive breast cancer includes: history and physical exam, a complete blood cell count, liver function tests, bilateral diagnostic mammography, breast Ultrasonography if necessary; tumour ER and PR determinations, HER-2 tumour status determination and pathology review. Mammography and thorough clinical workup in every suspected patient result in initiating early management.

show abstract

An Evaluation of Radionuclide Bone Scanning and Liver Ultrasonography for Staging Breast Cancer

Cited by 18 publications

References 25 publications

Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer

Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer

Mucinous Breast Carcinoma: Anatomo-Clinical Radiological and Therapeutic Features

Need for Routine X-Ray Chest and Ultrasonography of Liver in Workup, Diagnosis and Staging of Early Carcinoma of Breast in Patients Presenting First Time: A Prospective Single Institutional Study

Contact Info

Product

Resources

About